Skip to main content
OpenTrials
Completed

NCT Number: NCT04269941

Prognostic Factors Affecting Survival of Gastric GIST

Gastrointestinal stromal tumor (GIST) is the most common non-epithelial mesenchymal tumor of the gastrointestinal tract. Surgical treatment is the only curative therapy for primary localized GIST. This study aimed to identify the clinicopathological characteristics of gastric GISTs and to study the predictive factors for recurrence in Tunisian patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastric GIST

Age range

10 year–90 year

Sex eligibility

All sexes

Study type

Observational

About this study

The prognosis of gastric GIST depends on various tumor factors with the most important being the mitotic index and tumor necrosis. Imatinib therapy has revolutionized the treatment of advanced GIST.

They have been the subject of much controversy in terms of their histogenesis, classification, treatment and prognosis. GISTs are histologically similar to smooth muscle and nerve tumors such as leiomyomas, leiomyosarcomas or schwannomas. Currently they are well characterized with the recent discovery of the C-KIT gene mutation and the expression by tumor cells of the C-KIT protein.

Moreover, the discovery of this receptor is at the origin of the introduction of a "targeted therapy": an anti-tyrosine kinase molecule having revolutionized the therapeutic management of these tumors. However, the standard curative treatment of GIST remains complete surgical resection with negative margin from the tumor.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patient having gastric GIST

-

Exclusion criteria

  • patient operated for other gastric tumors

Treatment and study plan

total or subtotal gastrectomy

Other

resection of the gastric tumor

Primary outcomes

  1. number of patients operated for gastric GIST

    Time frame: 30 days

    the patient having adenocarcinoma or other histopathological type are excluded

Sponsors and collaborators

Lead sponsor

Université de Sousse

Other

Registry information

Official study title

Clinicopathological Characteristics and Prognostic Factors of Gastrointestinal Stromal Tumors Located in the Stomach in Tunisian Patients

Important dates

Study start
2000
Primary completion
2015
Study completion
2018
First posted
Feb 17, 2020
Registry last updated
Feb 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.